Aimmune Therapeutics Inc. (NASDAQ:AIMT) Receives $36.25 Consensus PT from Brokerages
Shares of Aimmune Therapeutics Inc. (NASDAQ:AIMT) have earned an average recommendation of “Buy” from the six brokerages that are presently covering the firm. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $36.25.
A number of research firms have recently issued reports on AIMT. Zacks Investment Research cut Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, August 15th. Wedbush restated an “outperform” rating and set a $42.00 price objective on shares of Aimmune Therapeutics in a research report on Monday, June 13th. Piper Jaffray Cos. restated an “overweight” rating and set a $38.00 price objective on shares of Aimmune Therapeutics in a research report on Tuesday, June 14th. Finally, JMP Securities began coverage on Aimmune Therapeutics in a research report on Monday, September 26th. They set an “outperform” rating and a $30.00 price objective on the stock.
Shares of Aimmune Therapeutics (NASDAQ:AIMT) opened at 15.00 on Monday. The stock’s market capitalization is $633.81 million. The company has a 50 day moving average of $15.08 and a 200 day moving average of $13.61. Aimmune Therapeutics has a 52-week low of $9.77 and a 52-week high of $22.01.
Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings results on Wednesday, August 10th. The company reported ($0.43) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by $0.01. Analysts predict that Aimmune Therapeutics will post ($1.75) EPS for the current fiscal year.
In related news, insider Mary M. Rozenman sold 30,000 shares of the business’s stock in a transaction on Thursday, September 8th. The stock was sold at an average price of $16.80, for a total value of $504,000.00. Following the sale, the insider now owns 30,000 shares of the company’s stock, valued at approximately $504,000. The sale was disclosed in a legal filing with the SEC, which is available through this link. 24.56% of the stock is owned by corporate insiders.
A number of hedge funds have recently made changes to their positions in AIMT. Schwab Charles Investment Management Inc. raised its stake in shares of Aimmune Therapeutics by 94.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 51,994 shares of the company’s stock valued at $563,000 after buying an additional 25,278 shares in the last quarter. American Century Companies Inc. raised its position in Aimmune Therapeutics by 4.5% in the second quarter. American Century Companies Inc. now owns 98,261 shares of the company’s stock worth $1,063,000 after buying an additional 4,201 shares in the last quarter. Metropolitan Life Insurance Co. NY raised its position in Aimmune Therapeutics by 116.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 20,796 shares of the company’s stock worth $225,000 after buying an additional 11,179 shares in the last quarter. Highbridge Capital Management LLC acquired a new position in Aimmune Therapeutics during the second quarter worth approximately $230,000. Finally, Parametric Portfolio Associates LLC raised its position in Aimmune Therapeutics by 23.4% in the second quarter. Parametric Portfolio Associates LLC now owns 48,270 shares of the company’s stock worth $522,000 after buying an additional 9,156 shares in the last quarter. 68.87% of the stock is currently owned by institutional investors and hedge funds.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.